CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
MMIC to Develop Platform for Quicker Optimization of OSD Formulations
Partnership between CPI, University of Strathclyde, GSK and AstraZeneca to utilize continuous manufacturing process. MMIC Grand Challenge 1 underway with CMAC at University of Strathclyde..... more
GSK and AZ on continuous manufacturing platform ‘grand challenge’
A consortium between CPI and University of Strathclyde aims to create a direct compression platform for continuous manufacturing of oral solid dosage drugs.
ReMediES Legacy Training
CMAC was a partner in ReMediES. An output of the project is this training package now online..... more